Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
E: Joanna.johnson@acrux.com.au
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
36
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,522.70 | 324.90 | -4.14% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,314.86 | 2,231.07 | -5.50% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,373.82 | 2,475.99 | -10.84% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,416.19 | 2,364.39 | -7.00% |
| NZX 50 Index | 11,793.55 | 431.73 | -3.53% |
| S&P 500 | 5,074.08 | 322.44 | -5.97% |
| S&P/ASX 200 | 7,346.70 | 321.10 | -4.19% |
| SSE Composite Index | 3,130.17 | 211.84 | -6.34% |